In terms of adjuvant therapy, HGASC patients exhibit significantly lower survival rates than other breast cancer subtypes, particularly those with tumor diameters >2 cm, lymph node metastasis, and ER-/PR-negative status, which are associated with higher recurrence risks and shorter disease-free survival (19). The gene discussed is ESR1; the disease is metastatic malignant neoplasm in the lymph nodes.